Targeting the cell cycle in breast cancer: towards the next phase

CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought

(2018) Mary E. Klein et al.   CANCER CELL

Abstract P1-09-03: Global knockdown of cellular kinases identifies MPS1 as a novel modulator of endocrine and palbociclib resistance highlighting a new role for MPS1 inhibitors

(2018) J Nikitorowicz-Buniak et al.   CANCER RESEARCH

Abstract PD4-01: The role of FGF/FGFR axis in resistance to SERDs and CDK4/6 inhibitors in ER+ breast cancer

(2018) P Mao et al.   CANCER RESEARCH

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer

(2018) Chrysiis Michaloglou et al.   MOLECULAR CANCER THERAPEUTICS

Once and only once: mechanisms of centriole duplication and their deregulation in disease

(2018) Erich A. Nigg et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers

(2018) Masanori Kawakami et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer

(2018) K. L. Thu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Over-elongation of centrioles in cancer promotes centriole amplification and chromosome missegregation

(2018) Gaëlle Marteil et al.   Nature Communications

Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer

(2018) Nirmesh Patel et al.   Nature Communications

PLK4: a link between centriole biogenesis and cancer

(2017) Radhika Radha Maniswami et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

TTK Inhibitors as a Targeted Therapy for CTNNB1 ( β -catenin) Mutant Cancers

(2017) Guido J.R. Zaman et al.   MOLECULAR CANCER THERAPEUTICS

HER2-positive breast cancer is lost in translation: time for patient-centered research

(2017) Isabelle Gingras et al.   Nature Reviews Clinical Oncology

Am I ready for CRISPR? A user's guide to genetic screens

(2017) John G. Doench   NATURE REVIEWS GENETICS

Integrative cancer pharmacogenomics to establish drug mechanism of action: drug repurposing

(2017) Nehme El-Hachem et al.   PHARMACOGENOMICS

Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer

(2017) Jacqueline M. Mason et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tuning Chromosomal Instability to Optimize Tumor Fitness

(2017) Mark E. Burkard et al.   Cancer Discovery

APC/C Dysfunction Limits Excessive Cancer Chromosomal Instability

(2017) Laurent Sansregret et al.   Cancer Discovery

Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer

(2016) Ryan A. Denu et al.   BMC CANCER

Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer

(2016) Romualdo Barroso-Sousa et al.   Breast Care

Predictive approaches for drug combination discovery in cancer

(2016) Seyed Ali Madani Tonekaboni et al.   BRIEFINGS IN BIOINFORMATICS

Abstract CT066: First-in-human phase I trial of the oral PLK4 inhibitor CFI-400945 in patients with advanced solid tumors

(2016) Philippe L. Bedard et al.   CANCER RESEARCH

Abstract P3-06-02: Characterization of resistance to the selective CDK4/6 inhibitor palbociclib in ER positive breast cancer

(2016) C Lenihan et al.   CANCER RESEARCH

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

(2016) Maria Teresa Herrera-Abreu et al.   CANCER RESEARCH

A USP28–53BP1–p53–p21 signaling axis arrests growth after centrosome loss or prolonged mitosis

(2016) Bramwell G. Lambrus et al.   JOURNAL OF CELL BIOLOGY

53BP1 and USP28 mediate p53 activation and G1 arrest after centrosome loss or extended mitotic duration

(2016) Franz Meitinger et al.   JOURNAL OF CELL BIOLOGY

Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity

(2016) A. M. Wengner et al.   MOLECULAR CANCER THERAPEUTICS

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

(2016) Giampaolo Bianchini et al.   Nature Reviews Clinical Oncology

Treating cancer with selective CDK4/6 inhibitors

(2016) Ben O'Leary et al.   Nature Reviews Clinical Oncology

Insights into APC/C: from cellular function to diseases and therapeutics

(2016) Zhuan Zhou et al.   Cell Division

Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts

(2016) Ines Lohse et al.   Oncotarget

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

(2016) Shawn F. Johnson et al.   Cell Reports

53BP1 and USP28 mediate p53-dependent cell cycle arrest in response to centrosome loss and prolonged mitosis

(2016) Chii Shyang Fong et al.   eLife

Progress with palbociclib in breast cancer: latest evidence and clinical considerations

(2016) Andrea Rocca et al.   Therapeutic Advances in Medical Oncology

The Molecular Biology of Spindle Assembly Checkpoint Signaling Dynamics

(2015) Andrea Musacchio   CURRENT BIOLOGY

Discovery of Imidazo[1,2-b]pyridazine Derivatives: Selective and Orally Available Mps1 (TTK) Kinase Inhibitors Exhibiting Remarkable Antiproliferative Activity

(2015) Ken-ichi Kusakabe et al.   JOURNAL OF MEDICINAL CHEMISTRY

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Targeting Mitosis in Cancer: Emerging Strategies

(2015) Carmen Dominguez-Brauer et al.   MOLECULAR CELL

Spatiotemporal regulation of the anaphase-promoting complex in mitosis

(2015) Sushama Sivakumar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Molecular basis underlying resistance to Mps1/TTK inhibitors

(2015) A Koch et al.   ONCOGENE

Chronic centrosome amplification without tumorigenesis

(2015) Benjamin Vitre et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rampant centrosome amplification underlies more aggressive disease course of triple negative breast cancers

(2015) Vaishali Pannu et al.   Oncotarget

Functional Characterization of CFI-400945, a Polo-like Kinase 4 Inhibitor, as a Potential Anticancer Agent

(2014) Jacqueline M. Mason et al.   CANCER CELL

The role of mitotic kinases in coupling the centrosome cycle with the assembly of the mitotic spindle

(2014) G. Wang et al.   JOURNAL OF CELL SCIENCE

Cyclin-dependent kinases

(2014) Marcos Malumbres   GENOME BIOLOGY

Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer

(2014) F Al-Ejeh et al.   Oncogenesis

Characterization of novel MPS1 inhibitors with preclinical anticancer activity

(2013) M Jemaà et al.   CELL DEATH AND DIFFERENTIATION

The Omics of Triple-Negative Breast Cancers

(2013) H. Xu et al.   CLINICAL CHEMISTRY

Regulation of Autophosphorylation Controls PLK4 Self-Destruction and Centriole Number

(2013) Inês Cunha-Ferreira et al.   CURRENT BIOLOGY

Structure-Based Design of Orally Bioavailable 1H-Pyrrolo[3,2-c]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1)

(2013) Sébastien Naud et al.   JOURNAL OF MEDICINAL CHEMISTRY

Effects of the Selective MPS1 Inhibitor MPS1-IN-3 on Glioblastoma Sensitivity to Antimitotic Drugs

(2013) Bakhos A. Tannous et al.   JNCI-Journal of the National Cancer Institute

Luminal breast cancer: from biology to treatment

(2013) Michail Ignatiadis et al.   Nature Reviews Clinical Oncology

Control of cell cycle transcription during G1 and S phases

(2013) Cosetta Bertoli et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The MPS1 Family of Protein Kinases

(2012) Xuedong Liu et al.   Annual Review of Biochemistry

The Spindle Assembly Checkpoint

(2012) Pablo Lara-Gonzalez et al.   CURRENT BIOLOGY

Selective killing of p53-deficient cancer cells by SP600125

(2012) Mohamed Jemaà et al.   EMBO Molecular Medicine

The autoregulated instability of Polo-like kinase 4 limits centrosome duplication to once per cell cycle

(2012) A. J. Holland et al.   GENES & DEVELOPMENT

A Clinical Overview of Centrosome Amplification in Human Cancers

(2012) Jason Yongsheng Chan   International Journal of Biological Sciences

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

(2012) Christina Curtis et al.   NATURE

NLK Is a Novel Therapeutic Target for PTEN Deficient Tumour Cells

(2012) Ana M. Mendes-Pereira et al.   PLoS One

Characterization of the Cellular and Antitumor Effects of MPI-0479605, a Small-Molecule Inhibitor of the Mitotic Kinase Mps1

(2011) K. D. Tardif et al.   MOLECULAR CANCER THERAPEUTICS

Treatment of HER2-positive breast cancer: current status and future perspectives

(2011) Carlos L. Arteaga et al.   Nature Reviews Clinical Oncology

High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells

(2011) J. Daniel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Functional Viability Profiles of Breast Cancer

(2011) R. Brough et al.   Cancer Discovery

Mechanisms of Endocrine Resistance in Breast Cancer

(2010) C. Kent Osborne et al.   Annual Review of Medicine

Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase

(2010) R. Colombo et al.   CANCER RESEARCH

Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1–C-Mad2 core complex

(2010) Laura Hewitt et al.   JOURNAL OF CELL BIOLOGY

Microtubule-binding agents: a dynamic field of cancer therapeutics

(2010) Charles Dumontet et al.   NATURE REVIEWS DRUG DISCOVERY

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

(2010) J L Dean et al.   ONCOGENE

Transcriptional regulation of the cyclin D1 gene at a glance

(2008) E. A. Klein et al.   JOURNAL OF CELL SCIENCE

Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials

(2007) Michele De Laurentiis et al.   JOURNAL OF CLINICAL ONCOLOGY